JP2003528609A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003528609A5 JP2003528609A5 JP2001570742A JP2001570742A JP2003528609A5 JP 2003528609 A5 JP2003528609 A5 JP 2003528609A5 JP 2001570742 A JP2001570742 A JP 2001570742A JP 2001570742 A JP2001570742 A JP 2001570742A JP 2003528609 A5 JP2003528609 A5 JP 2003528609A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- protein
- angiogenic activity
- isolated
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 description 23
- 230000001772 anti-angiogenic effect Effects 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 108010008217 nidogen Proteins 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102100037369 Nidogen-1 Human genes 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 206010000050 Abdominal adhesions Diseases 0.000 description 1
- 241000144080 Alestes Species 0.000 description 1
- 208000003120 Angiofibroma Diseases 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 102400000729 Arresten Human genes 0.000 description 1
- 101800001248 Arresten Proteins 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102400000730 Canstatin Human genes 0.000 description 1
- 101800000626 Canstatin Proteins 0.000 description 1
- 208000003732 Cat-scratch disease Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- FNQQBFNIYODEMB-UHFFFAOYSA-N Meticrane Chemical compound C1CCS(=O)(=O)C2=C1C=C(C)C(S(N)(=O)=O)=C2 FNQQBFNIYODEMB-UHFFFAOYSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 102400001051 Restin Human genes 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 102400000731 Tumstatin Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000013058 Weber syndrome Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000007293 brain stem infarction Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 108010038764 cytoplasmic linker protein 170 Proteins 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 229960003738 meticrane Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 108010012374 type IV collagen alpha3 chain Proteins 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19287100P | 2000-03-29 | 2000-03-29 | |
| US60/192,871 | 2000-03-29 | ||
| PCT/US2001/040382 WO2001073025A2 (en) | 2000-03-29 | 2001-03-28 | Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003528609A JP2003528609A (ja) | 2003-09-30 |
| JP2003528609A5 true JP2003528609A5 (https=) | 2008-05-08 |
Family
ID=22711364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001570742A Pending JP2003528609A (ja) | 2000-03-29 | 2001-03-28 | バスコスタチンおよび他のニドゲンドメインの抗血管形成特性および抗腫瘍特性 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1268798B1 (https=) |
| JP (1) | JP2003528609A (https=) |
| AT (1) | ATE328081T1 (https=) |
| AU (1) | AU8727401A (https=) |
| CA (1) | CA2403515A1 (https=) |
| DE (1) | DE60120131T2 (https=) |
| NZ (1) | NZ521567A (https=) |
| WO (1) | WO2001073025A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2389751A1 (en) * | 1999-11-01 | 2001-05-10 | Curagen Corporation | Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same |
| CN1455682A (zh) | 2001-01-05 | 2003-11-12 | 百疗医株式会社 | 包括编码抗－血管生成蛋白或者其部分的基因的用于类风湿性关节炎的基因治疗的组合物 |
| US7407660B2 (en) | 2003-04-16 | 2008-08-05 | Genentech, Inc. | Methods and compositions for selective modulation of vascularization |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6013628A (en) * | 1994-02-28 | 2000-01-11 | Regents Of The University Of Minnesota | Method for treating conditions of the eye using polypeptides |
-
2001
- 2001-03-28 EP EP01962422A patent/EP1268798B1/en not_active Expired - Lifetime
- 2001-03-28 AU AU8727401A patent/AU8727401A/xx not_active Withdrawn
- 2001-03-28 NZ NZ521567A patent/NZ521567A/en unknown
- 2001-03-28 AT AT01962422T patent/ATE328081T1/de not_active IP Right Cessation
- 2001-03-28 CA CA002403515A patent/CA2403515A1/en not_active Abandoned
- 2001-03-28 WO PCT/US2001/040382 patent/WO2001073025A2/en not_active Ceased
- 2001-03-28 DE DE60120131T patent/DE60120131T2/de not_active Expired - Fee Related
- 2001-03-28 JP JP2001570742A patent/JP2003528609A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104507489B (zh) | 用于预防和治疗类风湿性关节炎的组合物 | |
| JPH10502349A (ja) | インテグリンα▲下４▼β▲下１▼のＶＣＡＭ−１またはフィブロネクチンへの結合を阻害する方法 | |
| CN106866814B (zh) | Dpp-4抑制剂 | |
| EP3998077B1 (en) | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | |
| EP1038011B1 (en) | Methods of producing anti-angiogenic proteins; endostatin, angiostatin or restin, using a pichia yeast expression system | |
| KR20110069020A (ko) | 지혈 활성을 가지고 혈소판 응집을 유도할 수 있는 재조합 단백질 | |
| WO2008051505A2 (en) | Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage | |
| JPH07504886A (ja) | 細胞調節因子のインヒビターおよびはん痕形成を予防または緩和する方法 | |
| JP2000503856A (ja) | Ｂｐｉ融合タンパク質及びｂｐｉ由来ペプチドの微生物での組換え製造のための方法 | |
| US5239058A (en) | Proteins having anticoagulant properties | |
| JPH02222684A (ja) | 植物性リボソーム不活化タンパク質をコードするヌクレオチド配列 | |
| JPH05506646A (ja) | ヒト・フォンビルブラント因子のクローニング及び製造、並びにその使用方法 | |
| CN1143371A (zh) | 司登尼亚蛋白小体-司登尼亚钙蛋白 | |
| JP2003528609A5 (https=) | ||
| WO2001055359A1 (en) | A novel recombinant staphylokinase derivant and its preparation method and application thereof | |
| US5587457A (en) | Neutrophil stimulating peptides | |
| JP2003528610A5 (https=) | ||
| JP2673659B2 (ja) | ペプチド | |
| CN106916210A (zh) | 一种具有抗脑缺血作用的多肽及其应用 | |
| JPH025892A (ja) | 組換えヒトインターロイキン―１αポリペプチド | |
| JPH09512422A (ja) | カイメース阻害活性を有するα−１−抗キモトリプシン類似体 | |
| US5807828A (en) | Platelet aggregation inhibitors | |
| JP2009536821A (ja) | 新規血栓溶解分子及びその製造法 | |
| JP2002523100A (ja) | 新規なヒトリゾチーム遺伝子、それによりコードされたポリペプチド、およびそれらの作製方法 | |
| JP3095771B2 (ja) | ヒトフィブロネクチンポリペプチド類似体のクローニング及び製造並びにこのようなポリペプチド類似体の使用法 |